GliaMed Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

GliaMed General Information

Description

Developer of regenerative immunophilin ligands intended to provide stem cell therapy and tissue regeneration. The company's therapy provides development-stage biopharmaceutical services, enabling healthcare researchers to discover and develop small molecule drugs which enhance the human body's innate ability to regenerate.

Contact Information

Website
www.gliamed.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1072 South De Anza Boulevard
  • Suite A107-538
  • San Jose, CA 95129
  • United States
+1 (408)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 1072 South De Anza Boulevard
  • Suite A107-538
  • San Jose, CA 95129
  • United States
+1 (408)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GliaMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Oct-2021 Completed Generating Revenue
4. Later Stage VC 01-May-2009 Completed Generating Revenue
3. Later Stage VC (Series A1) 22-Oct-2008 Completed Generating Revenue
2. Grant 01-Jan-2006 $554K $500K Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2002 $500K $500K Completed Generating Revenue
To view GliaMed’s complete valuation and funding history, request access »

GliaMed Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A1
Series A
To view GliaMed’s complete cap table history, request access »

GliaMed Patents

  • 151

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • Pending

  • Expiring in next 12 mo

GliaMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100317711-A1 Stem-like cells and method for reprogramming adult mammalian somatic cells Inactive 17-Dec-2008
AU-2008338989-A1 Stem-like cells and method for reprogramming adult mammalian somatic cells Inactive 17-Dec-2007
EP-2242838-A1 Stem-like cells and method for reprogramming adult mammalian somatic cells Inactive 17-Dec-2007
CA-2709566-A1 Stem-like cells and method for reprogramming adult mammalian somatic cells Inactive 17-Dec-2007
US-20100330063-A1 Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells Inactive 17-Dec-2007 C12N5/0618
To view GliaMed’s complete patent history, request access »

GliaMed Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.S. Department of Health and Human Services Government
To view GliaMed’s complete investors history, request access »

Ready to get started?

Request a free trial

GliaMed FAQs

  • When was GliaMed founded?

    GliaMed was founded in 2001.

  • Where is GliaMed headquartered?

    GliaMed is headquartered in San Jose, CA.

  • What industry is GliaMed in?

    GliaMed’s primary industry is Drug Discovery.

  • Is GliaMed a private or public company?

    GliaMed is a Private company.

  • What is GliaMed’s current revenue?

    The current revenue for GliaMed is .

  • How much funding has GliaMed raised over time?

    GliaMed has raised $4.32M.

  • Who are GliaMed’s investors?

    U.S. Department of Health and Human Services has invested in GliaMed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »